Abstract
Pulmonary fibrosis is a devastating chronic lung disease characterized by irreparable lung tissue scarring, leading to a progressive loss in lung capacity. A critical component of clinical management is the accurate assessment of lung function decline, often measured via Forced Vital Capacity (FVC). This paper introduces Fibrosis-Net, a deep convolutional neural network (CNN) specifically tailored to predict pulmonary fibrosis progression by fusing chest CT imaging with clinical metadata. Leveraging machine-driven design exploration, the proposed architecture achieves state-of-the-art performance on the OSIC Pulmonary Fibrosis Progression Challenge dataset. Furthermore, explainability-driven validation confirms that the model utilizes clinically relevant visual indicators, such as honeycombing, to inform its predictions.
Introduction
Predicting the progression of pulmonary fibrosis is a significant challenge in respiratory medicine. The disease's trajectory is highly variable, and visual indicators in computed tomography (CT) scans—such as ground-glass opacities or cystic "honeycombing"—can be subtle or mimic other pathologies. Clinicians rely on FVC measurements to track decline, but a reliable automated method to predict future FVC values from initial scans and metadata has remained elusive.
Existing AI approaches often struggle with the high dimensionality of CT data or operate as "black boxes," lacking the transparency required for clinical adoption. Fibrosis-Net addresses these issues through a specialized architecture designed via automated exploration and a focus on clinical interpretability.
Methodology
The development of Fibrosis-Net is centered on three technical pillars: machine-driven design, a tailored architecture for high-dimensional data, and multimodal fusion.
Machine-Driven Design Exploration
Rather than relying on manual architectural tuning, the authors employed a generative synthesis approach. This algorithmic strategy explores a vast space of potential network designs to identify an optimal balance between representational power and computational efficiency. The resulting backbone is optimized specifically for the nuances of CT lung analysis.
The PRPE Architecture
The core of Fibrosis-Net is the Projection-Replication-Projection-Expansion (PRPE) block. This design utilizes lightweight depthwise and pointwise convolutions to process CT stacks efficiently. To further align the model with clinical reality, the researchers implemented a "Lower 55%" heuristic, focusing the network's attention on the lower lung lobes where fibrotic changes are typically most prevalent.
Multimodal Fusion and Explainability
Fibrosis-Net does not rely on imagery alone. It integrates clinical metadata—including age, sex, smoking status, and initial spirometry measurements—late in the architecture to predict the linear rate of FVC change. To ensure the model's decisions are based on pathology rather than image artifacts, the authors utilized GSInquire. This explainability tool audits the decision-making process, verifying that the model focuses on relevant features like honeycombing areas used by radiologists.
Experimental Results
The model was evaluated using the OSIC Pulmonary Fibrosis Progression Challenge dataset, comprising 172 training cases and a dedicated test set. Performance was measured using the Modified Laplace Log Likelihood, a metric that penalizes both prediction error and overconfidence.
As shown in the results, Fibrosis-Net achieved a score of -6.8188, significantly outperforming the first-place Kaggle solution (-6.8305). Given the logarithmic nature of the scale, this represents a substantial improvement in predictive reliability and accuracy over previous state-of-the-art models.
Discussion and Conclusion
Fibrosis-Net demonstrates the power of combining automated architectural search with clinical domain knowledge. By focusing on the lower lung regions and incorporating metadata, the model achieves superior predictive performance while maintaining a level of transparency through explainability-driven validation.
Despite these gains, the authors note that Fibrosis-Net is not yet a production-ready clinical tool. The dataset size (approximately 200 patients) remains small for deep learning standards, and further validation in "human-in-the-loop" clinical scenarios is necessary. However, as part of the OpenMedAI initiative, the open-source release of Fibrosis-Net provides a robust foundation for future research into chronic lung disease progression.
Summary updated